#Sweden #Stockholm #Sobi #Hemophilia #ITP

Sobi to Present Latest Research at ISTH Congress 2025

Sobi, a biopharmaceutical company renowned for developing treatments for rare diseases, is gearing up to present significant clinical study updates at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress scheduled to take place from June 21 to 25, 2025, in Washington. With a total of ten presentations lined up, Sobi’s clinical teams are expected to unveil new research and findings that could potentially change the landscape for patients with hemophilia and immune thrombocytopenia (ITP).

Dr. Lydia Abad-Franch, Head of Research and Development and Chief Medical Officer at Sobi, expressed the company's commitment to sharing knowledge and collaborating with the global community to enhance treatment options for patients affected by these conditions. “Interacting at ISTH is essential for our ongoing efforts to bring forward innovative therapies for individuals living with hemophilia, ITP, and other rare blood disorders,” she stated.

Key Presentations

One of the highlights of Sobi’s participation at ISTH 2025 is the presentation of clinical data regarding avatrombopag, a medication designed for the treatment of children with ITP, and efanesoctocog alfa, which will cover surgical outcomes in patients. Notably, Sobi's abstracts will feature diverse research, including a long-term extension study for hemophilia patients, demonstrating consistent improvements in joint health and other critical outcomes.

Dr. Abad-Franch emphasized the urgency of addressing the needs of patients with rare diseases, stating, “There are many unmet needs in this population, and we are proud to advance treatment options through more data and scientific understanding.”

Overview of Key Data to be Presented

• - ALTUVOCT® (efanesoctocog alfa): A major subject of focus, this treatment is crucial for managing bleeding episodes in hemophilia patients. Presentations will include:

- OC 64.4: Major surgical outcomes observed with efanesoctocog alfa, four years’ data from the XTEND Clinical Program. (Presenting author: Liane Khoo)
- OC 20.5: Analysis on treating bleeding episodes with efanesoctocog alfa in children. (Presenting author: Lynn Malec)

• - General Hemophilia Studies: Presentations will address unmet medical needs and health inequities in hemophilia A, along with data from ongoing observational studies.

• - Doptelet® (avatrombopag): This medication is aimed at treating children with ITP, and includes presentations such as consistent treatment responses across a diverse patient population.

Company Background

Sobi, or Swedish Orphan Biovitrum AB, is committed to unlocking the potential of innovation in biopharmaceuticals to enhance the quality of life for patients with rare diseases. Employing around 1,900 professionals worldwide and generating significant revenue growth, Sobi continues to prioritize scientific research and development in the hemophilia and ITP sectors. The company’s collaboration with major pharmaceutical partners, like Sanofi, also plays a vital role in driving forward the discovery and commercialization of treatment options for rare blood disorders.

Through their presentations at ISTH 2025, Sobi aims to further elevate the conversation around rare diseases while working towards solutions that tackle the significant challenges patients face today. This commitment reaffirms their dedication to advancing medical research and improving patient outcomes globally.